Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd (000766.SZ): Plans to acquire the controlling stake in Bajia Pharmaceutical to deepen its layout in the field of neurological diseases.

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (000766.SZ) announced that on August 6, 2026, its wholly-owned subsidiary Guilin Jinma Innovation Investment Co., Ltd. (referred to as Guilin Jinma) jointly signed a "Merger Intent Agreement" with Bajia Pharmaceutical Co., Ltd. (referred to as Bajia), aiming for Guilin Jinma to acquire the controlling stake in Bajia. It is reported that Bajia is an innovative pharmaceutical company focused on the research and development of original innovative drugs, registered in the Guilin Economic and Technological Development Zone. The company has obtained 23 patents for drug research and development, and holds clinical approvals for 2 categories of first-class chemical drugs and 1 category of first-class traditional Chinese medicine. The signing of this intent agreement is an important measure for the company to deepen its layout in the field of nervous system diseases and accelerate its strategic transformation. It will help the company leverage the target company's original drug research and development platform and product pipeline to further enrich its innovative product layout in the neurological field, enhance its overall competitiveness and long-term value in the pharmaceutical innovation sector, and promote the company's complete transformation into a comprehensive pharmaceutical enterprise led by research and development innovation.